Cargando…

The therapeutic properties of resminostat for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer with increases in new cases being reported annually. Histopathologists have identified hepatic steatosis as a characteristic of a broad range of chronic liver diseases that are associated with the onset and development of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jun, Gray, Steven G., Wabitsch, Martin, Greene, Catherine M., Lawless, Matthew W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049311/ https://www.ncbi.nlm.nih.gov/pubmed/30035186 http://dx.doi.org/10.18632/oncoscience.420

Ejemplares similares

Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis
por: Soukupova, Jitka, et al.
Publicado: (2017)

Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma
por: Streubel, Gundula, et al.
Publicado: (2021)

Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma
por: Karagianni, Fani, et al.
Publicado: (2021)

Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma
por: Ruf, Benjamin, et al.
Publicado: (2015)

Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma
por: Karagianni, Fani, et al.
Publicado: (2022)

Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma
por: Barbhuiya, Mustafa A., et al.
Publicado: (2017)

Sgo1 is a potential therapeutic target for hepatocellular carcinoma
por: Wang, Lyu-Han, et al.
Publicado: (2015)

Multi-target siRNA: Therapeutic Strategy for Hepatocellular Carcinoma
por: Li, Tiejun, et al.
Publicado: (2016)

Sustained release of therapeutic gene by injectable hydrogel for hepatocellular carcinoma
por: Xu, Shuangta, et al.
Publicado: (2023)

Therapeutic vaccine to cure large mouse hepatocellular carcinomas
por: Han, Zhen, et al.
Publicado: (2017)

TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma
por: Zhou, Dong-Sheng, et al.
Publicado: (2015)

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
por: Tan, Wenliang, et al.
Publicado: (2018)

A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy
por: Ueno, Makoto, et al.
Publicado: (2021)

Plasma metabolomic analysis of human hepatocellular carcinoma: Diagnostic and therapeutic study
por: Chen, Yang, et al.
Publicado: (2016)

Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy
por: Lawless, Matthew W, et al.
Publicado: (2009)

Identification of ACSF gene family as therapeutic targets and immune-associated biomarkers in hepatocellular carcinoma
por: Zhao, Zijin, et al.
Publicado: (2022)

Aminoacylase 3 Is a New Potential Marker and Therapeutic Target in Hepatocellular Carcinoma
por: Tsirulnikov, Kirill, et al.
Publicado: (2018)

Integrative analysis of h-prune as a potential therapeutic target for hepatocellular carcinoma
por: Liao, Haotian, et al.
Publicado: (2019)

Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review
por: Falette Puisieux, Manon, et al.
Publicado: (2022)

Novel therapeutic features of disulfiram against hepatocellular carcinoma cells with inhibitory effects on a disintegrin and metalloproteinase 10
por: Goto, Kaku, et al.
Publicado: (2018)

CHCHD2 promotes hepatocellular carcinoma and indicates poor prognosis of hepatocellular carcinoma patients
por: Yao, Yang, et al.
Publicado: (2019)

Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties
por: Cai, Jialin, et al.
Publicado: (2017)

Screening therapeutic targets of ribavirin in hepatocellular carcinoma
por: Xu, Chen, et al.
Publicado: (2018)

Lamin B1 is a potential therapeutic target and prognostic biomarker for hepatocellular carcinoma
por: Yang, Yongyu, et al.
Publicado: (2022)

Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma
por: Li, Meng, et al.
Publicado: (2016)

Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma
por: Gong, Jun, et al.
Publicado: (2020)

Na(+)/K(+)-ATPase α1 subunit, a novel therapeutic target for hepatocellular carcinoma
por: Zhuang, Liping, et al.
Publicado: (2015)

Therapeutic efficacy of dendritic cell injection in advanced hepatocellular carcinoma: the role of natural killer and T lymphocytes
por: Zaghloul, Amr, et al.
Publicado: (2022)

Meiotic nuclear divisions 1 promotes proliferation and metastasis in hepatocellular carcinoma and is a potential diagnostic and therapeutic target gene
por: Tan, Kai, et al.
Publicado: (2022)

Clinical significance and therapeutic value of glutathione peroxidase 3 (GPx3) in hepatocellular carcinoma
por: Qi, Xiang, et al.
Publicado: (2014)

Roles of Therapeutic Bioactive Compounds in Hepatocellular Carcinoma
por: Jain, Divya, et al.
Publicado: (2021)

MT1G is Silenced by DNA Methylation and Contributes to the Pathogenesis of Hepatocellular Carcinoma
por: Zeng, Ju-deng, et al.
Publicado: (2018)

Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines
por: Zhang, Zhi, et al.
Publicado: (2020)

NF-κB regulation: the nuclear response
por: Mankan, Arun K, et al.
Publicado: (2009)

Discovery of NKCC1 as a potential therapeutic target to inhibit hepatocellular carcinoma cell growth and metastasis
por: Zhou, Yaya, et al.
Publicado: (2017)

Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications
por: Huang, Xiaowen, et al.
Publicado: (2020)

Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility
por: Ferrín, Gustavo, et al.
Publicado: (2015)

Development of MicroRNA Therapeutics for Hepatocellular Carcinoma
por: Aravalli, Rajagopal N.
Publicado: (2013)

Hepatocellular Carcinoma—How to Determine Therapeutic Options
por: Mehta, Neil
Publicado: (2020)

New Therapeutic Options for Advanced Hepatocellular Carcinoma
por: Ma, Yu-Shui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i5scaj7t6nd00t8ltrp11rgnm5